Cover Image
市場調查報告書

骨關節炎的全球市場:2015年∼2019年

Global Osteoarthritis Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 326313
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
骨關節炎的全球市場:2015年∼2019年 Global Osteoarthritis Market 2015-2019
出版日期: 2015年03月18日 內容資訊: 英文 93 Pages
簡介

骨關節炎,是緩和關節衝擊的軟骨無法正常作用的狀態。全球骨關節炎市場,2014年∼2019年預計以8.55%的年複合成長率成長。

本報告提供全球骨關節炎市場相關調查分析、市場規模與成長率、市場趨勢、市場的推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 關於疾病
  • 病因與病理學
  • 流行病學
  • 危險因素
  • 症狀
  • 診斷
  • 骨關節炎的管理

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 美國的骨關節炎市場
    • 市場規模與預測
  • 波特的五力分析

第8章 骨關節炎開發平台的評估

第9章 市場區隔:各藥物分類

第10章 地區區分

第11章 購買標準

第12章 推動市場成長要素

第13章 成長推動因素與其影響

第14章 市場課題

第15章 成長推動因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第19章 主要供應商分析

  • Abbott Laboratories
  • Johnson & Johnson
  • Novartis
  • Pfizer

第20章 相關報告

圖表

目錄
Product Code: IRTNTR5334

About OA

OA is a condition in which the cartilage, a material that cushions the joints, breaks down. This leads to stiffness, inflammation, pain, and loss of joint movement. The exact etiology of OA is not fully understood. Obesity, overuse of the joint, weak thigh muscles, aging, and genetics are some of the common risk factors of OA; OA symptoms usually develop progressively. At first, there may be stiffness that appears to be more a niggle than a medical concern. Treatment is given depending on the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.

TechNavio's analysts forecast the Global OA market to grow at a CAGR of 8.55 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global OA market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the symptomatic treatment and therapeutics of OA that are available in the market. The market can be divided into three segments: Anti-inflammatories, Pain Relievers, and Drugs to Restore Articular Cartilage.

TechNavio's report, the Global OA Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global OA market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Abbott Laboratories
  • Johnson & Johnson
  • Novartis
  • Pfizer

Other Prominent Vendors

  • Abiogen Pharma
  • Ampio pharmaceuticals
  • BioDelivery Sciences International
  • CrystalGenomics
  • Daiichi Sankyo
  • Eli Lilly
  • Horizon Pharma
  • Iroko Pharmaceuticals
  • Merck
  • Nuvo Research
  • Regeneus
  • Sanofi
  • SantoSolve
  • Smith & Nephew
  • Winston Pharmaceuticals

Market Driver

  • Increase in Global Aging Population
  • For a full, detailed list, view our report

Market Challenge

  • Low Treatment Seeking Rate
  • For a full, detailed list, view our report

Market Trend

  • Increased Competition
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Etiology and Pathophysiology
  • 06.3. Epidemiology
    • 06.3.1. Global Prevalence of Osteoarthritis
    • 06.3.2. Prevalence of Osteoarthritis in US
    • 06.3.3. Prevalence of Osteoarthritis in UK
    • 06.3.4. Prevalence of Osteoarthritis in Canada
  • 06.4. Risk Factors
  • 06.5. Symptoms
  • 6.6. Diagnosis
    • 06.6.1. Clinical History
    • 06.6.2. Physical Examination
    • 06.6.3. Diagnostic Imaging Techniques
  • 06.7. Management of Osteoarthritis
    • 06.7.1. Non-pharmacological Therapy
    • 06.7.2. Pharmacological Therapy
    • 06.7.3. Surgical Treatment

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Osteoarthritis Market in US
    • 07.3.1. Market Size and Forecast
  • 07.4. Five Forces Analysis

08. Osteoarthritis Pipeline Assessment

09. Market Segmentation by Drug Class

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. Abbott Laboratories
    • 18.2.2. Johnson & Johnson
    • 18.2.3. Novartis
    • 18.2.4. Pfizer
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Abbott Laboratories
    • 19.1.1. Key Facts
    • 19.1.2. Business Description
    • 19.1.3. Business Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Revenue by Business Segmentation
    • 19.1.6. Revenue Comparison 2011 and 2012
    • 19.1.7. Revenue by Geographical Segmentation
    • 19.1.8. Key Information
    • 19.1.9. SWOT Analysis
  • 19.2. Johnson & Johnson
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation by Revenue 2013
    • 19.2.4. Business Segmentation by Revenue 2012 and 2013
    • 19.2.5. Geographical Segmentation by Revenue 2013
    • 19.2.6. Business Strategy
    • 19.2.7. Recent Developments
    • 19.2.8. SWOT Analysis
  • 19.3. Novartis
    • 19.3.1. Key Facts
    • 19.3.2. Business Description
    • 19.3.3. Business Segmentation
    • 19.3.4. Revenue by Business Segmentation
    • 19.3.5. Revenue Comparison 2012 and 2013
    • 19.3.6. Sales by Geography
    • 19.3.7. Business Strategy
    • 19.3.8. Key Developments
    • 19.3.9. SWOT Analysis
  • 19.4. Pfizer
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation by Revenue 2013
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Geographical Segmentation by Revenue
    • 19.4.6. Business Strategy
    • 19.4.7. Key Developments
    • 19.4.8. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Etiology and Pathophysiology of Osteoarthritis
  • Exhibit 3: Global Prevalence of Osteoarthritis 2014-2019 (million)
  • Exhibit 4: Prevalence of Osteoarthritis in US 2009
  • Exhibit 5: Prevalence Rate of Osteoarthritis in US 2009
  • Exhibit 6: Prevalence of Osteoarthritis in UK 2013
  • Exhibit 7: Prevalence of Current and Future Osteoarthritis Cases by Gender in Canada 2010-2040
  • Exhibit 8: Diagnostic Imaging Techniques for Osteoarthritis
  • Exhibit 9: Management of Osteoarthritis
  • Exhibit 10: Global Osteoarthritis Market 2014-2019 (US$ billion)
  • Exhibit 11: Osteoarthritis Market in US 2014-2019 (US$ billion)
  • Exhibit 12: Segmentation of Global Osteoarthritis Market by Drug Class
  • Exhibit 13: Segmentation of Global Osteoarthritis Market by Geography 2014
  • Exhibit 14: Worldwide Estimated Growth of Osteoarthritis Population 2010-2020 (Age Groups in Year)
  • Exhibit 15: Prevalence of Osteoarthritis 2012 and 2022 (million)
  • Exhibit 16: Unmet Medical Needs with Current Osteoarthritis Treatments
  • Exhibit 17: Global Incidence of Osteoarthritis in Overweight and Normal Weight Individuals 2013 (Percent)
  • Exhibit 18: Future Therapeutics in Treatment of Osteoarthritis
  • Exhibit 19: Abbott Laboratories: Revenue Segmentation 2013
  • Exhibit 20: Abbott Laboratories: Product Profile
  • Exhibit 21: Johnson & Johnson: Sales by Therapeutic Area (Pharmaceuticals) 2013
  • Exhibit 22: Product Profile: Johnson & Johnson (Dolormin Gel)
  • Exhibit 23: Product Profile: Johnson & Johnson (Monovisc)
  • Exhibit 24: Product Profile: Johnson & Johnson (Orthovisc)
  • Exhibit 25: Product Profile: Johnson & Johnson (Tolectin)
  • Exhibit 26: Product Profile: Novartis
  • Exhibit 27: Global Revenue of Voltaren 2010-2013 (US$ million)
  • Exhibit 28: Revenue of Voltaren in US 2011-2013 (US$ million)
  • Exhibit 29: Product Profile: Novartis
  • Exhibit 30: Product Profile: Pfizer (Ansaid)
  • Exhibit 31: Product Profile: Pfizer (Arthrotec)
  • Exhibit 32: Product Profile: Pfizer (Celebrex)
  • Exhibit 33: Global Revenue of Celebrex 2010-2013 (US$ million)
  • Exhibit 34: Product Profile: Pfizer (Daypro)
  • Exhibit 35: Product Profile: Pfizer (Feldene)
  • Exhibit 36: Product Profile: Pfizer (Motrin)
  • Exhibit 37: Product Profile: Pfizer (Ponstel)
  • Exhibit 38: Abbott Laboratories: Business Segmentation
  • Exhibit 39: Abbott Laboratories: Revenue by Business Segmentation 2012
  • Exhibit 40: Abbott Laboratories: Revenue by Business Segmentation 2011 and 2012 (US$ million)
  • Exhibit 41: Abbott Laboratories: Revenue by Geographical Segmentation 2012
  • Exhibit 42: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 43: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 44: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 45: Novartis: Business Segmentation
  • Exhibit 46: Novartis: Revenue by Business Segmentation 2013
  • Exhibit 47: Novartis: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 48: Novartis: Revenue by Geographical Segmentation 2013
  • Exhibit 49: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 50: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 51: Pfizer: Geographical Segmentation by Revenue 2013
Back to Top